Literature DB >> 19142732

Multicentric investigation of ionising radiation-induced cell death as a predictive parameter of individual radiosensitivity.

Burkhard Greve1, Kristin Dreffke, Astrid Rickinger, Stefan Könemann, Eberhard Fritz, Friederike Eckardt-Schupp, Susanne Amler, Cristina Sauerland, Herbert Braselmann, Wiebke Sauter, Thomas Illig, Peter Schmezer, Maria Gomolka, Normann Willich, Tobias Bölling.   

Abstract

In the present study, the predictive value of ionising radiation (IR)-induced cell death was tested in peripheral blood lymphocytes (PBLs) and their corresponding Epstein-Barr virus-transformed lymphoblastoid cell lines (LCLs) in an interlaboratory comparison. PBLs and their corresponding LCLs were derived from 15 tumour patients, that were considered clinically radiosensitive based on acute side-effects, and matched controls. Upon coding of the samples, radiosensitivity of the matched pairs was analysed in parallel in three different laboratories by assessing radiation-induced apoptotic and necrotic cell death using annexin V. All participating laboratories detected a dose-dependent increase of apoptosis and necrosis in the individual samples, to a very similar extent. However, comparing the mean values of apoptotic and necrotic levels derived from PBLs of the radiosensitive cohort with the mean values of the control cohort did not reveal a significant difference. Furthermore, within 15 matched pairs, no sample was unambiguously and independently identified by all three participating laboratories to demonstrate in vitro hypersensitivity that matched the clinical hypersensitivity. As has been reported previously, apoptotic and necrotic cell death is barely detectable in immortalised LCL derivatives using low doses of IR. Concomitantly, the differences in apoptosis or necrosis levels found in primary cells of different individuals were not observed in the corresponding LCL derivatives. All participating laboratories concordantly reasoned that, with the methods applied here, IR-induced cell death in PBLs is unsuitable to unequivocally predict the individual clinical radiosensitivity of cancer patients. Furthermore, LCLs do not reflect the physiological properties of the corresponding primary blood lymphocytes with regard to IR-induced cell death. Their value to predict clinical radiosensitivity is thus highly questionable.

Entities:  

Mesh:

Year:  2009        PMID: 19142732     DOI: 10.1007/s10495-008-0294-6

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  9 in total

1.  Increased sensitivity of HPV-positive head and neck cancer cell lines to x-irradiation ± Cisplatin due to decreased expression of E6 and E7 oncoproteins and enhanced apoptosis.

Authors:  Frank Ziemann; Andrea Arenz; Stefanie Preising; Claus Wittekindt; Jens P Klussmann; Rita Engenhart-Cabillic; Andrea Wittig
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

2.  Survivin, a target to modulate the radiosensitivity of Ewing's sarcoma.

Authors:  B Greve; F Sheikh-Mounessi; B Kemper; I Ernst; M Götte; H T Eich
Journal:  Strahlenther Onkol       Date:  2012-10-10       Impact factor: 3.621

3.  Chromosomal radiosensitivity and acute radiation side effects after radiotherapy in tumour patients--a follow-up study.

Authors:  Reinhard Huber; Herbert Braselmann; Hans Geinitz; Irene Jaehnert; Adolf Baumgartner; Reinhard Thamm; Markus Figel; Michael Molls; Horst Zitzelsberger
Journal:  Radiat Oncol       Date:  2011-04-07       Impact factor: 3.481

4.  Combined low initial DNA damage and high radiation-induced apoptosis confers clinical resistance to long-term toxicity in breast cancer patients treated with high-dose radiotherapy.

Authors:  Luis Alberto Henríquez-Hernández; Ruth Carmona-Vigo; Beatriz Pinar; Elisa Bordón; Marta Lloret; María Isabel Núñez; Carlos Rodríguez-Gallego; Pedro C Lara
Journal:  Radiat Oncol       Date:  2011-06-06       Impact factor: 3.481

5.  Differential Impact of Membrane-Bound and Soluble Forms of the Prognostic Marker Syndecan-1 on the Invasiveness, Migration, Apoptosis, and Proliferation of Cervical Cancer Cells.

Authors:  Katharina Hilgers; Sherif Abdelaziz Ibrahim; Ludwig Kiesel; Burkhard Greve; Nancy A Espinoza-Sánchez; Martin Götte
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

6.  Evaluation of different biomarkers to predict individual radiosensitivity in an inter-laboratory comparison--lessons for future studies.

Authors:  Burkhard Greve; Tobias Bölling; Susanne Amler; Ute Rössler; Maria Gomolka; Claudia Mayer; Odilia Popanda; Kristin Dreffke; Astrid Rickinger; Eberhard Fritz; Friederike Eckardt-Schupp; Christina Sauerland; Herbert Braselmann; Wiebke Sauter; Thomas Illig; Dorothea Riesenbeck; Stefan Könemann; Normann Willich; Simone Mörtl; Hans Theodor Eich; Peter Schmezer
Journal:  PLoS One       Date:  2012-10-23       Impact factor: 3.240

7.  Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.

Authors:  Christof Bernemann; Carolin Hülsewig; Christian Ruckert; Sarah Schäfer; Lena Blümel; Georg Hempel; Martin Götte; Burkhard Greve; Peter J Barth; Ludwig Kiesel; Cornelia Liedtke
Journal:  Mol Cancer       Date:  2014-07-17       Impact factor: 27.401

8.  Knockdown of Musashi RNA Binding Proteins Decreases Radioresistance but Enhances Cell Motility and Invasion in Triple-Negative Breast Cancer.

Authors:  Fabian M Troschel; Annemarie Minte; Yahia Mahmoud Ismail; Amr Kamal; Mahmoud Salah Abdullah; Sarah Hamdy Ahmed; Marie Deffner; Björn Kemper; Ludwig Kiesel; Hans Theodor Eich; Sherif Abdelaziz Ibrahim; Martin Götte; Burkhard Greve
Journal:  Int J Mol Sci       Date:  2020-03-21       Impact factor: 5.923

9.  Knockdown of the prognostic cancer stem cell marker Musashi-1 decreases radio-resistance while enhancing apoptosis in hormone receptor-positive breast cancer cells via p21WAF1/CIP1.

Authors:  Martin Götte; Burkhard Greve; Fabian M Troschel; Heike Palenta; Katrin Borrmann; Kristin Heshe; San Hue Hua; George W Yip; Ludwig Kiesel; Hans Theodor Eich
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-22       Impact factor: 4.553

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.